177Lu-DOTATATE治疗后显像诊断颅内非典型脑膜瘤肺转移
本文报告一例54岁男性非典型(WHO II级)脑膜瘤患者,接受1周期肽受体放射性核素治疗后行全身177Lu-DOTATATE显像,发现既往未检测到的肺部脑膜瘤转移所致胸部摄取。该病例提示应考虑罕见/非典型转移部位,以及放射性示踪剂全身显像在识别这些转移中的价值。
要点
- 非典型(WHO II级)脑膜瘤可发生远处转移,肺转移为罕见但需考虑的部位。
- 既往影像局限于头部时,治疗后全身177Lu-DOTATATE显像可发现既往未检测到的肺转移。
- 放射性示踪剂全身显像有助于识别脑膜瘤的罕见/非典型转移部位。
核心结论
- 该病例强调应考虑罕见/非典型转移部位,以及放射性示踪剂全身显像在识别这些转移中的价值。
研究设计与样本
- 病例报告:一例54岁男性非典型(WHO II级)脑膜瘤患者,接受1周期肽受体放射性核素治疗。
主要发现
- 治疗后全身177Lu-DOTATATE显像显示胸部摄取,来源于既往未检测到的肺部脑膜瘤转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningiomas are typically benign solitary intracranial tumors. Atypical (World Health Organization [WHO] grade II) or malignant/anaplastic (WHO grade III) meningiomas are seldom, and distant metastases occur only in rare exceptions. We present a case of a 54-year-old male patient with atypical (WHO grade II) meningioma who underwent 1 cycle of peptide receptor radionuclide therapy. Previous imaging studies were confined to the head, but posttherapeutic whole-body Lu-DOTATATE scintigraphy revealed thoracic uptake arising from previously undetected pulmonic meningioma metastases. The case highlights the importance of consideration of rare/untypical metastatic sides and the value of radiotracer whole-body imaging in identifying these.
引用
- Backhaus P, Huss S, Kösek V, et al. Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy. Clin Nucl Med. 2018. PMID: 29688946. doi:10.1097/RLU.0000000000002077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。